Evaluation on short-term prognosis of hepatitis B patients with acute-on-chronic liver failure using MELD and PT

( views:454, downloads:0 )
Author:
ZHOU Jian(No. 5 Liver Diseases Department, Ningbo Infectious Disease Hospital, Ningbo 315000, China)
YE Jun-mao(No. 5 Liver Diseases Department, Ningbo Infectious Disease Hospital, Ningbo 315000, China)
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 1, Issue 04, 2008
DOI:
Key Word:
Chronic hepatitis B;liver failure;Model for end-stage liver disease;Prothrombintime;Prognosis

Abstract: Objective To compare the model for end-stage liver disease (MELD) and PT in survival prediction of hepatitis B patients with acute-on-chronic liver failure. Methods One hundred and thirty-nine hepatitis B patients with acute-on-chronic liver failure were divided into survival and death group, and evaluated by MELD and FT. The area under ROC curve was used to compare the MELD and PT. The mortality was observed within 3 months. Results The MELD score and PT of survival group was 25.09 ± 3.92 and (26.46 ± 6.46) seconds respectively, and those for the death group were 36.25 ± 6.42 and (40.78 ± 10.80) seconds. The differences were of statistical significance ( P < 0.01 ). MELD score showed significant correlations with PT(r =0.824, P <0.01). The area under ROC curve was 0.936 (95% CI 0.895 ± 0.977 ) on MELD score and 0. 890 (95 % CI 0.839 ± 0.941 ) on PT, and there was no significant difference between them. Conclusions Both MELD score and PT can accurately predict the short-term prognosis of hepatitis B patients with acute-on-chronic liver failure. The validity of prognosis by MELD is similar to PT. The mortality increases with the MELD score and PT increasing.

  • [1]Kamath PS,Wiesner RH,Malinchoc M,et al.A model to predict survival in patients with end-stage liver disease.Hepatology,2001,33(2):464-470.
  • [2]Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases and Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association.Diagnostic and treatment guideline for liver failure.Zhonghua Chuanranbing Zazhi,2006,24(6):422-425.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南.中华传染病杂志,2006,24(6):422-425.
  • [3]Liang KH.Hepatology.Beijing:People's Medical Publish House,1995:203-207.梁扩寰.肝脏病学.北京:人民卫生出版社,1995:203-207.
  • [4]Botta F,Giannini E,Romagnoli P,et al.MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function:a European study.Gut,2003,52(1):134-139.
  • [5]Wiesner R,Edwards E,Freeman R,et al.Model for end-stage liver disease (MELD) and allocation of donor livers.Gastroenterology,2003,124(1):91-96.
  • [6]Xiong WJ,Liu F,Zhao ZX,et al.Clinical significance of model for end-stage liver disease in the prognosis evaluation of patients with liver cirrhosis.Zhongguo Shiyongneike Zazhi,2005,25 (2):132-133.熊伍军,刘菲,赵中辛,等.终末期肝病模型对肝硬化住院患者预后评估的临床意义.中国实用内科杂志,2005,25(2):132-133.
  • [7]Mao DW,Qiu H,Hu ZB.Advances on the application of model for end-stage liver disease in liver failure.Zhengguo Weizhongbing Jijiu Yixue,2006,18(7):441-443.毛德文,邱华,胡振斌.终末期肝病模型评分在肝功能衰竭中应用的研究进展.中国危重病急救医学,2006,18(7):441-443.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn